Pegargiminase
- Generic Name
- Pegargiminase
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1394129-74-8
- Unique Ingredient Identifier
- 0B7PYQ9YRT
- Background
Pegargiminase is an anticancer agent.
- Indication
Investigated for use/treatment in melanoma and hepatocellular carcinoma.
- Associated Conditions
- -
- Associated Therapies
- -
Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient
Phase 1
Completed
- Conditions
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 8
- Registration Number
- NCT01528384
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 43
- Registration Number
- NCT01497925
- Locations
- 🇺🇸
University of California at Davis, Sacramento, California, United States
A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
- First Posted Date
- 2011-01-20
- Last Posted Date
- 2014-11-20
- Lead Sponsor
- Barts & The London NHS Trust
- Target Recruit Count
- 70
- Registration Number
- NCT01279967
- Locations
- 🇬🇧
The Royal Sussex County Hospital, Brighton, United Kingdom
🇬🇧Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧Hull and East Yorkshire Hospitals NHS Trust,The Princess Royal Hospital, Hull, United Kingdom
Testing of ADI-PEG in Hepatocellular Carcinoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-03-27
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- FDA Office of Orphan Products Development
- Target Recruit Count
- 34
- Registration Number
- NCT00056992
- Locations
- 🇺🇸
MD Anderson Cancer center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath